Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

A neurotensin analog blocks cocaine-conditioned place preference and reinstatement.

Boules M, Netz R, Fredrickson PA, Richelson E.

Behav Pharmacol. 2016 Apr;27(2-3 Spec Issue):236-9. doi: 10.1097/FBP.0000000000000227.

PMID:
26901162
2.

Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Boules MM, Fredrickson P, Muehlmann AM, Richelson E.

Behav Sci (Basel). 2014 Jun 13;4(2):125-53. doi: 10.3390/bs4020125. eCollection 2014 Jun. Review.

3.

Neurotensin agonist attenuates nicotine potentiation to cocaine sensitization.

Fredrickson P, Boules M, Stennett B, Richelson E.

Behav Sci (Basel). 2014 Jan 22;4(1):42-52. doi: 10.3390/bs4010042. eCollection 2014 Mar.

4.

Mechanism of mesenchymal stem cell-induced neuron recovery and anti-inflammation.

Huang P, Gebhart N, Richelson E, Brott TG, Meschia JF, Zubair AC.

Cytotherapy. 2014 Oct;16(10):1336-44. doi: 10.1016/j.jcyt.2014.05.007. Epub 2014 Jun 11.

PMID:
24927715
5.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

6.

Neurotensin agonists in the regulation of food intake.

Fredrickson P, Boules M, Richelson E.

Int J Obes (Lond). 2014 Mar;38(3):474. doi: 10.1038/ijo.2013.129. Epub 2013 Jul 17. No abstract available.

PMID:
23860334
7.

New model of action for mood stabilizers: phosphoproteome from rat pre-frontal cortex synaptoneurosomal preparations.

Corena-McLeod M, Walss-Bass C, Oliveros A, Gordillo Villegas A, Ceballos C, Charlesworth CM, Madden B, Linser PJ, Van Ekeris L, Smith K, Richelson E.

PLoS One. 2013 May 14;8(5):e52147. doi: 10.1371/journal.pone.0052147. Print 2013.

8.

In reply.

Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL.

Mayo Clin Proc. 2013 Apr;88(4):420. doi: 10.1016/j.mayocp.2013.01.020. No abstract available.

PMID:
23541018
9.

Diverse roles of neurotensin agonists in the central nervous system.

Boules M, Li Z, Smith K, Fredrickson P, Richelson E.

Front Endocrinol (Lausanne). 2013 Mar 22;4:36. doi: 10.3389/fendo.2013.00036. eCollection 2013.

10.

Multi-modality: a new approach for the treatment of major depressive disorder.

Richelson E.

Int J Neuropsychopharmacol. 2013 Jul;16(6):1433-1442. Epub 2013 Jan 30.

11.

Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications.

Krystal AD, Richelson E, Roth T.

Sleep Med Rev. 2013 Aug;17(4):263-72. doi: 10.1016/j.smrv.2012.08.001. Epub 2013 Jan 26. Review.

PMID:
23357028
12.

Considerations on safety concerns about citalopram prescribing.

Sheeler RD, Ackerman MJ, Richelson E, Nelson TK, Staab JP, Tangalos EG, Dieser LM, Cunningham JL.

Mayo Clin Proc. 2012 Nov;87(11):1042-5. doi: 10.1016/j.mayocp.2012.07.009. Epub 2012 Sep 24. No abstract available.

13.

NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain.

Smith KE, Boules M, Williams K, Richelson E.

Behav Brain Res. 2012 Jun 15;232(1):93-7. doi: 10.1016/j.bbr.2012.03.044. Epub 2012 Apr 5.

PMID:
22504145
14.

Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain.

Guillemette A, Dansereau MA, Beaudet N, Richelson E, Sarret P.

Eur J Pain. 2012 Apr;16(4):473-84. doi: 10.1016/j.ejpain.2011.07.008.

PMID:
22396077
15.

Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action.

Zhu HJ, Appel DI, Gründemann D, Richelson E, Markowitz JS.

Pharmacol Res. 2012 Apr;65(4):491-6. doi: 10.1016/j.phrs.2012.01.008. Epub 2012 Feb 8.

PMID:
22342816
16.

The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia.

Smith KE, Boules M, Williams K, Fauq AH, Richelson E.

Behav Brain Res. 2011 Oct 31;224(2):344-9. doi: 10.1016/j.bbr.2011.06.014. Epub 2011 Jun 21.

17.

Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine.

Boules M, Johnston H, Tozy J, Smith K, Li Z, Richelson E.

Behav Pharmacol. 2011 Sep;22(5-6):573-81. doi: 10.1097/FBP.0b013e3283474a3a.

PMID:
21691202
18.

Sensorimotor gating in NTS1 and NTS2 null mice: effects of d-amphetamine, dizocilpine, clozapine and NT69L.

Oliveros A, Heckman MG, Del Pilar Corena-McLeod M, Williams K, Boules M, Richelson E.

J Exp Biol. 2010 Dec 15;213(Pt 24):4232-9. doi: 10.1242/jeb.046318.

19.

A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats.

Boules M, Oliveros A, Liang Y, Williams K, Shaw A, Robinson J, Fredrickson P, Richelson E.

Neuropeptides. 2011 Feb;45(1):9-16. doi: 10.1016/j.npep.2010.09.003. Epub 2010 Nov 2.

PMID:
21047685
20.

Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2.

Lee MR, Hinton DJ, Unal SS, Richelson E, Choi DS.

Alcohol Clin Exp Res. 2011 Jan;35(1):99-107. doi: 10.1111/j.1530-0277.2010.01326.x. Epub 2010 Oct 6.

21.

NT69L blocks ethanol-induced increase of dopamine and glutamate levels in striatum of mouse.

Li Z, Boules M, Richelson E.

Neurosci Lett. 2011 Jan 10;487(3):322-4. doi: 10.1016/j.neulet.2010.10.048. Epub 2010 Oct 23.

PMID:
20974215
22.

New antipsychotic drugs: how do their receptor-binding profiles compare?

Richelson E.

J Clin Psychiatry. 2010 Sep;71(9):1243-4. doi: 10.4088/JCP.10ac06470yel. Review. No abstract available.

PMID:
20923625
23.

Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia.

Li Z, Boules M, Williams K, Gordillo A, Li S, Richelson E.

Neurobiol Dis. 2010 Nov;40(2):467-77. doi: 10.1016/j.nbd.2010.07.011. Epub 2010 Jul 24.

24.

Systemically and topically active antinociceptive neurotensin compounds.

Rossi GC, Matulonis JE, Richelson E, Barbut D, Pasternak GW.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):1075-9. doi: 10.1124/jpet.109.165282. Epub 2010 Jun 24.

25.

Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

Liang Y, Boules M, Li Z, Williams K, Miura T, Oliveros A, Richelson E.

Neuropharmacology. 2010 Jun;58(8):1199-205. doi: 10.1016/j.neuropharm.2010.02.015. Epub 2010 Mar 6.

26.
27.

Neurotensin receptor type 1 regulates ethanol intoxication and consumption in mice.

Lee MR, Hinton DJ, Song JY, Lee KW, Choo C, Johng H, Unal SS, Richelson E, Choi DS.

Pharmacol Biochem Behav. 2010 Apr;95(2):235-41. doi: 10.1016/j.pbb.2010.01.012. Epub 2010 Feb 1.

28.

The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.

Li Z, Boules M, Williams K, Peris J, Richelson E.

Brain Res. 2010 Jan 22;1311:28-36. doi: 10.1016/j.brainres.2009.11.048. Epub 2009 Nov 27.

29.

NT79: A novel neurotensin analog with selective behavioral effects.

Boules M, Liang Y, Briody S, Miura T, Fauq I, Oliveros A, Wilson M, Khaniyev S, Williams K, Li Z, Qi Y, Katovich M, Richelson E.

Brain Res. 2010 Jan 13;1308:35-46. doi: 10.1016/j.brainres.2009.10.050. Epub 2009 Oct 27.

30.

Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.

Briody S, Boules M, Oliveros A, Fauq I, Richelson E.

Behav Brain Res. 2010 Feb 11;207(1):118-24. doi: 10.1016/j.bbr.2009.09.044. Epub 2009 Oct 2.

31.

NT69L, a novel analgesic, shows synergy with morphine.

Boules M, Shaw A, Liang Y, Barbut D, Richelson E.

Brain Res. 2009 Oct 19;1294:22-8. doi: 10.1016/j.brainres.2009.07.086. Epub 2009 Aug 3.

PMID:
19651107
32.

Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity.

Roussy G, Dansereau MA, Baudisson S, Ezzoubaa F, Belleville K, Beaudet N, Martinez J, Richelson E, Sarret P.

Mol Pain. 2009 Jul 6;5:38. doi: 10.1186/1744-8069-5-38.

33.

Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial.

Bouras EP, Talley NJ, Camilleri M, Burton DD, Heckman MG, Crook JE, Richelson E.

Am J Gastroenterol. 2008 Aug;103(8):2043-50.

34.

Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial.

Lisanby SH, Husain MM, Rosenquist PB, Maixner D, Gutierrez R, Krystal A, Gilmer W, Marangell LB, Aaronson S, Daskalakis ZJ, Canterbury R, Richelson E, Sackeim HA, George MS.

Neuropsychopharmacology. 2009 Jan;34(2):522-34. doi: 10.1038/npp.2008.118. Epub 2008 Aug 13.

35.

Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).

Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, Blazar E, Williams K, Zhang Y, Carlier PR, Richelson E.

J Pharmacol Exp Ther. 2008 Nov;327(2):573-83. doi: 10.1124/jpet.108.143610. Epub 2008 Aug 8.

36.

Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain.

Liang Y, Boules M, Shaw AM, Williams K, Fredrickson P, Richelson E.

Brain Res. 2008 Sep 22;1231:6-15. doi: 10.1016/j.brainres.2008.07.037. Epub 2008 Jul 19.

PMID:
18687313
37.

Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.

Corena-McLeod Mdel P, Oliveros A, Charlesworth C, Madden B, Liang YQ, Boules M, Shaw A, Williams K, Richelson E.

Brain Res. 2008 Oct 3;1233:8-19. doi: 10.1016/j.brainres.2008.07.021. Epub 2008 Jul 15.

PMID:
18657526
38.

Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model.

Roussy G, Dansereau MA, Doré-Savard L, Belleville K, Beaudet N, Richelson E, Sarret P.

J Neurochem. 2008 May;105(4):1100-14. doi: 10.1111/j.1471-4159.2007.05205.x. Epub 2007 Dec 25.

39.

Neurotensin agonists: potential in the treatment of schizophrenia.

Boules M, Shaw A, Fredrickson P, Richelson E.

CNS Drugs. 2007;21(1):13-23. Review.

PMID:
17190526
40.

The neurotensin receptor agonist NT69L suppresses sucrose-reinforced operant behavior in the rat.

Boules M, Iversen I, Oliveros A, Shaw A, Williams K, Robinson J, Fredrickson P, Richelson E.

Brain Res. 2007 Jan 5;1127(1):90-8. Epub 2006 Nov 17.

PMID:
17113052
41.

Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.

Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, Richelson E.

Eur J Pharmacol. 2007 Jan 19;555(1):30-6. Epub 2006 Oct 17.

PMID:
17109850
42.

Bioactive analogs of neurotensin: focus on CNS effects.

Boules M, Fredrickson P, Richelson E.

Peptides. 2006 Oct;27(10):2523-33. Epub 2006 Aug 1. Review.

PMID:
16882457
43.

Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.

Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Lavasseur BI, Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH.

J Clin Oncol. 2006 Jun 20;24(18):2836-41.

PMID:
16782922
44.

Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice.

Nguyen JH, Yamamoto S, Steers J, Sevlever D, Lin W, Shimojima N, Castanedes-Casey M, Genco P, Golde T, Richelson E, Dickson D, McKinney M, Eckman CB.

J Hepatol. 2006 Jun;44(6):1105-14. Epub 2005 Nov 7.

45.

Neurobiologic basis of nicotine addiction and psychostimulant abuse: a role for neurotensin?

Fredrickson P, Boules M, Lin SC, Richelson E.

Psychiatr Clin North Am. 2005 Sep;28(3):737-51, 746. Review.

PMID:
16122577
46.

Neurotensin agonists as an alternative to antipsychotics.

Boules M, Fredrickson P, Richelson E.

Expert Opin Investig Drugs. 2005 Apr;14(4):359-69. Review.

PMID:
15882113
47.

Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain.

Wang R, Boules M, Gollatz E, Williams K, Tiner W, Richelson E.

Brain Res Mol Brain Res. 2005 Jul 29;138(1):24-34.

PMID:
15878217
48.

Neurotensin receptor agonists and antagonists for schizophrenia.

Richelson E, Fredrickson PA, Boules MM.

Am J Psychiatry. 2005 Mar;162(3):633-4; author reply 635. No abstract available.

PMID:
15741499
49.

Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys.

Fantegrossi WE, Ko MC, Woods JH, Richelson E.

Pharmacol Biochem Behav. 2005 Feb;80(2):341-9. Epub 2004 Dec 30.

PMID:
15680187
50.

Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro.

Wang R, Boules M, Tiner W, Richelson E.

Brain Res. 2004 Oct 29;1025(1-2):21-8.

PMID:
15464740

Supplemental Content

Loading ...
Support Center